Serum biomarkers in evaluation and management of idiopathic pulmonary fibrosis
作者机构：Department of emergency wardFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300193China Department of Pancreatic and Gastric SurgeryNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China NHC Key Laboratory of Hormones and Development(Tianjn Medical University)Tianjin Key Laboratory of Metabolic DiseasesTianjn Medical University Chu Hsien-I Memorial Hospital&Tianjin Institute of EndocrinologyTianjin 300134China
出 版 物：《Precision Medicine Research》 (精准医学研究)
年 卷 期：2020年第2卷第3期
页 面：127-135页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Idiopathic pulmonary fibrosis Biomarkers Serum tumor makers
摘 要：Despite there has greater understanding of the pathophysiology in idiopathic pulmonary fibrosis,idiopathic pulmonary fibrosis still remains a challenge in clinical practice and translational research due to its *** in molecular techniques have identified potential pathways and targets for diagnosis and therapeutic *** types of idiopathic pulmonary fibrosis biomarkers such as KL-6,SP-A,SP-D,MMP7 and other potential ones have been studied *** addition,many studies have confirmed that levels of some tumor markers such as CA 19-9,CA 15-3,CEA,CA 125,CYFRA 21-1 are useful for idiopathic pulmonary *** present study focuses on serum biomarkers including tumor markers to provide an overview on the current roles of these biomarkers in the setting of diagnosis,prediction as well as response to therapy in idiopathic pulmonary fibrosis.
维普期刊数据库